Advertisement

Best of Journals

Best of Journals sessions are open to all attendees, and will be held in the General Session room. Expert faculty will take a multidisciplinary look over the best journal articles which have been published over the last year.

<

  Best of Journals: Prostate Cancer
Friday, January 31 - 7:00 AM - 7:45 AM
Urologist
Inger Rosner, MD
Walter Reed National Military Medical Center
1. Jacobs BL, Zhang Y, Schroeck FR, Skolarus TA, Wei JT, Montie JE, Gilbert SM, Strope SA, Dunn RL, Miller DC, Hollenbeck BK. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013 Jun 26;309(24):2587-95. doi: 10.1001/jama.2013.6882. PubMed PMID: 23800935; PubMed Central PMCID: PMC3857348.
2. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013 Jan 31;368(5):436-45. doi: 10.1056/NEJMoa1209978. PubMed PMID: 23363497; PubMed Central PMCID: PMC3742365.
Radiation Oncologist
Ronald Chen, MD, MPH
The University of North Carolina
1. Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tomé W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE. Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract. 2013 May;9(3):e90-5. doi: 10.1200/JOP.2013.001003. PubMed PMID: 23942508; PubMed Central PMCID: PMC3651578.
2. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, Stoyanova R, Movsas B, Greenberg RE, Uzzo RG, Ma C, Buyyounouski MK. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013 Nov 1;31(31):3860-8. doi: 10.1200/JCO.2013.51.1972. Epub 2013 Oct 7. PubMed PMID: 24101042; PubMed Central PMCID: PMC3805927.
3. Heemsbergen WD, Al-Mamgani A, Slot A, Dielwart MF, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2013 Nov 15. doi:pii: S0167-8140(13)00518-5. 10.1016/j.radonc.2013.09.026. [Epub ahead of print] PubMed PMID: 24246414.
Medical Oncologist
Marijo Bilusic, MD, PhD
Fox Chase Cancer Center
1. Parker C et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med, Volume 369(3):213-223, July 18, 2013
2. Margel D et al. Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes. J Clin Oncol. 2013 Sep;31(25):3069-75.
3. Arora VK et al. Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. Cell - 5 December 2013 (Vol. 155, Issue 6, pp. 1309-1322.
  Best of Journals:
Renal Cancer

Saturday, February 16 - 7:00 AM - 7:45 AM
Medical Oncologist
Elisabeth Heath, MD
Karmanos Cancer Institute, Wayne State University
1. Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial Brian I. Rini, Joaquim Bellmunt, Jill Clancy, Kongming Wang, Andreas G. Niethammer, Subramanian Hariharan, and Bernard Escudier JCO JCO.2013.50.5305; published online on December 2, 2013;
2. Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma Thomas E. Hutson, Bernard Escudier, Emilio Esteban, Georg A. Bjarnason, Ho Yeong Lim, Kenneth B. Pittman, Peggy Senico, Andreas Niethammer, Dongrui Ray Lu, Subramanian Hariharan, and Robert J. Motzer JCO JCO.2013.50.3961; published online on December 2, 2013;
Translational Research
James Mier, MD
Beth Israel Deaconess Medical Center
1. Li L, Shen C, Nakamura E, Ando K, Signoretti S, Beroukhim R, Cowley GS, Lizotte P, Liberzon E, Bair S, Root DE, Tamayo P, Tsherniak A, Cheng SC, Tabak B, Jacobsen A, Hakimi AA, Schultz N, Ciriello G, Sander C, Hsieh JJ, Kaelin WG Jr. SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer. Cancer Cell. 2013 Dec 9;24(6):738-50. doi: 10.1016/j.ccr.2013.10.025. PubMed PMID: 24332042.
2. Vanharanta S, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massagué J. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med. 2013 Jan;19(1):50-6. doi: 10.1038/nm.3029. Epub 2012 Dec 9. PubMed PMID: 23223005; PubMed Central PMCID: PMC3540187.
Urologist
Daniel Canter, MDEinstein Healthcare Network
1. Hamilton RJ, Morilla D, Cabrera F, Leapman M, Chen LY, Bernstein M, Hakimi AA, Reuter VE, Russo P. The association between statin medication and progression after surgery for localized renal cell carcinoma. J Urol. 2013 Nov 26. doi:pii: S0022-5347(13)06003-5. 10.1016/j.juro.2013.10.141. [Epub ahead of print] PubMed PMID: 24291547.
2. Macleod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, White E. Risk factors for renal cell carcinoma in the VITAL study. J Urol. 2013 Nov;190(5):1657-61. doi: 10.1016/j.juro.2013.04.130. Epub 2013 May 9. PubMed PMID: 23665301.
3. Trinh QD, Bianchi M, Hansen J, Tian Z, Abdollah F, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI, Sun M. In-hospital mortality and failure to rescue after cytoreductive nephrectomy. Eur Urol. 2013 Jun;63(6):1107-14. doi: 10.1016/j.eururo.2012.08.069. Epub 2012 Sep 7. PubMed PMID: 22981674.

Cosponsored by